Kailera Therapeutics, Inc.

What they do

Kailera is developing four clinical-stage GLP-1-based product candidates for obesity, in-licensed from Jiangsu Hengrui Pharmaceuticals for markets outside Greater China. Lead candidate ribupatide injection (KAI-9531) is a once-weekly GLP-1/GIP receptor dual agonist in Phase 3. The pipeline also includes ribupatide oral, KAI-7535 (oral small molecule GLP-1 agonist), and KAI-4729 (once-weekly GLP-1/GIP/glucagon tri-agonist).

Revenue drivers

• Ribupatide injection — Lead product candidate; no revenue yet as it is in Phase 3 trials; potential revenue depends on regulatory approval and commercialization.
• Ribupatide franchise (oral formulation) — Oral tablet version of ribupatide in development; no current revenue; intended to broaden the franchise with a convenient oral option.
• KAI-7535 and KAI-4729 — Earlier-stage oral small molecule GLP-1 agonist and injectable tri-agonist, respectively; no revenue; part of the diversified pipeline.

Recent performance

As of June 30, 2026, Kailera reported total assets of $1.21 billion, cash and equivalents of $130.3 million, total liabilities of $93.0 million, and shareholder equity of $1.12 billion. The company has no product revenue, being clinical-stage. In July 2026, Hengrui reported positive topline Phase 3 data for ribupatide injection in type 2 diabetes patients in China, with HbA1c reductions up to 2.67%. In August 2026, another Phase 3 trial showed HbA1c reductions of 2.78% (4 mg) and 2.34% (2 mg) versus 2.29% for semaglutide 1 mg.

Strategy

Kailera is focused on building a diversified GLP-1-based obesity pipeline to serve patients across the treatment journey. The company is advancing ribupatide injection through global Phase 3 trials while expanding the franchise with oral formulations. It is also developing KAI-7535 and KAI-4729 to address needs in oral and combination therapies. The collaboration with Hengrui provides exclusive rights outside Greater China, with Hengrui handling development and commercialization in Greater China.

Risks

• Clinical-stage, no revenue — Kailera has no approved products or revenue; all candidates are in clinical development and require years of trials and regulatory approval.
• Head-to-head efficacy risk — The company has not conducted head-to-head trials against approved obesity medications, so claims of superior weight loss are unproven.
• Dependence on Hengrui — All product candidates are in-licensed from Hengrui, and Kailera relies on Hengrui's development and commercialization in Greater China.
• Regulatory and approval risk — Even if trials succeed, there is no guarantee of regulatory approval or that product candidates will outperform existing therapies.

Outlook

Management expects to continue advancing ribupatide injection through Phase 3 trials and progressing the oral franchise and other candidates. The positive topline data from Hengrui's Phase 3 T2D trials support the clinical program, but U.S. development and commercialization remain several years away. No financial guidance is provided.